Dr. Stephen Squinto, Ph.D., is Chief Investment Officer of J.P. Morgan Life Science Private Capital (“LSPC”) within J.P. Morgan Prvate Capital, a division of J.P. Morgan Global Alternatives in J.P. Morgan Asset Management.

Stephen joined J.P. Morgan Private Capital in 2022. Stephen leads the Life Sciences and Healthcare Private Capital investment platform at J.P. Morgan, which leverages the global scale, robust healthcare service ecosystem and healthcare data intelligence of J.P. Morgan to invest in life sciences and healthcare companies.

Stephen has had a 35-year career in biotechnology and drug development.  He was an early team member and an early company builder of Regeneron Pharmaceuticals, Co-Founder of Alexion Pharmaceuticals, and subsequently a highly successful investor at OrbiMed Advisors.   While building Alexion, Dr. Squinto and his team were responsible for the discovery, development, approval and commercial launch of several life transforming biotechnology products worldwide serving several rare disease patient communities.  During his 8 years with OrbiMed, Dr. Squinto served on as many as 20 company boards, co-founded several OrbiMed-financed companies and served as an operating executive of five.  The investments led by Dr. Squinto at OrbiMed led to significant returns for the firm.

Stephen received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto previously held various joint academic positions at the Tulane University and LSU Medical Schools.